VPM1002 Market

As for March 26, 2020

1.Introduce of VPM1002?a Genetically Modified More Effective BCG Vaccine

VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.

The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.

Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.

2.Research Progress for VPM1002

Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.

The vaccine is currently being tested in a further Phase III study on adult volunteers in India.

3.VPM1002 Vaccine Clinical Experiment for Against Covid-19

Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.

Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.

The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.

VPM1002 Market contains market size and forecasts of VPM1002 (Tuberculosis BCG Based Vaccine) in global, including the following market information:

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Sales, 2017-2022, 2023-2028, (K Doses)

Global top five VPM1002 (Tuberculosis BCG Based Vaccine) companies in 2021 (%)

The global VPM1002 (Tuberculosis BCG Based Vaccine) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

by Dosage Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) include Vakzine Projekt Management (VPM) and Serum Institute of India etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the VPM1002 (Tuberculosis BCG Based Vaccine) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Segment Percentages, by Type, 2021 (%)

by Dosage

0.5ml Package

1ml Package

2ml Package

Other

by Type of Inoculator

Initial Vaccinate

Revaccination

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Segment Percentages, by Application, 2021 (%)

0-5 Years Old

5-18 Years Old

18-45 Years Old

45-65 Years Old

?65 Years Old

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies VPM1002 (Tuberculosis BCG Based Vaccine) revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies VPM1002 (Tuberculosis BCG Based Vaccine) revenues share in global market, 2021 (%)

Key companies VPM1002 (Tuberculosis BCG Based Vaccine) sales in global market, 2017-2022 (Estimated), (K Doses)

Key companies VPM1002 (Tuberculosis BCG Based Vaccine) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Vakzine Projekt Management (VPM)

Serum Institute of India